In a potential landmark announcement, the Irish Government has today become the first to fully publicly endorse DeepVerge’s COVID-19 Microtox® PD technology.
This follows extensive due diligence and numerous site visits as part of a detailed verification process. Recognising that a number of the original non-disclosure agreements (‘NDAs’) that DeepVerge entered with international government agencies (including the UK and European/Asian countries) are now also starting to fall away, other similar endorsements might be expected to follow shortly.
As part of today’s news, the Government of Ireland is formally supporting the Group’s Centre of Excellence in Cork with grant funding with a view to accelerating the process toward mass production, while an expansion of the original project through collaborations with industrial partners extends its scope well beyond SARS-CoV-2 to include numerous other current and prospective life-threatening pathogens.
Recognising that regulatory enforcement is likely to require domestic water authorities to replace current manual sampling processes with one capable of delivering instantaneous results combined with predictive analysis from the billions of litres being generated daily, prospective international demand (plus ongoing maintenance) for networked installations of Microtox® PD equipment could become very large indeed.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.
